1-(4-methoxyphenyl)-4,4-dimethylpentane

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(4-methoxyphenyl)-4,4-dimethylpentane
• 英文别名: 1-(4,4-Dimethylpentyl)-4-methoxybenzene
• 化学式: C₁₄H₂₂O
• 分子量: 206.328
• InChiKey: CSEDIDZFAYLMRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-(4-甲氧基苯基)丙基苯基亚砜 在 N-氯代丁二酰亚胺 、 异丙基氯化镁 作用下， 以 四氢呋喃 、 四氯化碳 为溶剂， 反应 17.0h， 生成 1-(4-methoxyphenyl)-4,4-dimethylpentane
  参考文献：
  名称：

  用格氏试剂从1-氯烷基苯基亚砜生成镁类胡萝卜素及其在烷基化和烯烃合成中的应用

  摘要：

  用格氏试剂在低温下处理1-氯烷基苯基亚砜，得到定量产率的镁类胡萝卜素。已发现生成的镁类胡萝卜素在低于-60°C的温度下可长期稳定，并且可与格氏试剂反应生成烷基化产物。生成的镁类胡萝卜素与各种锂α-磺酰基碳负离子的反应产生了具有良好碳收率的碳-碳键形成烯烃。该方法为制备烯烃提供了一种很好的方法。描述了上述反应的范围和限制。

  DOI：

  10.1016/j.tet.2004.04.063

文献信息

• METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY
  申请人：FOO Shi Yin

  公开号：US20120122844A1

  公开（公告）日：2012-05-17

  The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R 1 , R 2 , R 3 , R 5 , X, A 3 , B 1 , s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.

  本发明提供了中性内切肽酶抑制剂的使用，用于制造用于治疗、改善和/或预防造影剂诱导性肾病的药物。该发明还涉及使用化合物Formula I中的化合物：其中R1、R2、R3、R5、X、A3、B1、s和n在此处定义，用于治疗、改善和/或预防造影剂诱导性肾病。本发明进一步提供了用于治疗、改善和/或预防造影剂诱导性肾病的药理活性剂的组合。
• Nicotinamide Derivatives
  申请人：Blake Tanisha D.

  公开号：US20080146569A1

  公开（公告）日：2008-06-19

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.

  本发明涉及公式（I）的化合物及其药用可接受的盐和溶剂化合物，其中取代基如本文所定义，包含这种化合物的组合物以及这种化合物用于治疗各种疾病和状况，如哮喘。
• Substituted Aminobutyric Derivatives as Neprilysin Inhibitors
  申请人：Coppola Gary Mark

  公开号：US20120252830A1

  公开（公告）日：2012-10-04

  The present invention provides a compound of formula I′; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了公式I'的化合物；或其药学上可接受的盐，其中R1、R2、R3、X和n在此定义。本发明还涉及制造本发明化合物的方法及其治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。
• NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：Yoshida Tomohiro

  公开号：US20100228026A1

  公开（公告）日：2010-09-09

  The invention provides a sulfonyl malonamide derivative, or a pharmacologically acceptable salt thereof or a solvate thereof, that has therapeutic and/or preventive effect(s) on various diseases due to its agonist action at AT 2 receptor, and is useful as a pharmaceutical agent for the treatment and/or prevention of diseases involving the renin-angiotensin-aldosterone system (RAAS).

  该发明提供了一种磺酰基马隆酰胺衍生物，或其药理学上可接受的盐或溶剂，由于其在AT2受体上的激动剂作用，对各种疾病具有治疗和/或预防作用，并且作为用于治疗和/或预防涉及肾素-血管紧张素-醛固酮系统（RAAS）疾病的药物剂形具有用处。
• TRICYCLIC INDOLE-DERIVED SPIRO DERIVATIVES AS CRTH2 MODULATORS
  申请人：Crosignani Stefano

  公开号：US20120115895A1

  公开（公告）日：2012-05-10

  The present invention relates to compounds of formula (I) for use as pharmaceutical active compounds, as well as pharmaceutical formulations containing the same, for the treatment of allergic diseases. The compounds according to Formula (I) are suitable as modulators of CRTH2. The invention provides Spiro derivatives according to Formula (I) and related formulae that are useful in the treatment and/or prevention of diseases selected from allergic diseases such as allergic asthma, allergic rhinitis, allergic conjunctivitis, and inflammatory dermatoses such as atopic dermatitis, contact hypersensitivity, allergic contact dermatitis, chronic urticaria/chronic idiopathic/autoimmune urticaria, drag-induced exanthems (e.g., toxic epidermal necrolysis or Lyell's syndrome/Stevens-Johnson syndrome/drug hypersensitivity syndrome), photodermatosis or polymorphous light emption (e.g., photoirritant contact dermatitis, photoallergy contact dermatitis, chronic actinic dermatitis), and myositis neurodegenerative disorders such as neuropatic pain and other diseases with an inflammatory component such as rheumatoid arthritis, multiple sclerosis, osteoarthritis, and inflammatory bowel disease (IBD).

  本发明涉及式（I）的化合物作为药物活性化合物的用途，以及含有该化合物的药物制剂，用于治疗过敏性疾病。根据式（I）的化合物适用于CRTH2的调节剂。本发明提供了根据式（I）及相关式的螺环衍生物，其在过敏性疾病（如过敏性哮喘、过敏性鼻炎、过敏性结膜炎）以及炎症皮肤病（如特应性皮炎、接触性超敏性、过敏性接触性皮炎、慢性荨麻疹/慢性特发性/自身免疫性荨麻疹、药物诱发性皮疹（如毒性表皮坏死症或Lyell综合征/史蒂文斯-约翰逊综合征/药物过敏综合征）、光敏皮肤病或多形性光敏反应（如光致刺激性接触性皮炎、光致过敏接触性皮炎、慢性光性皮炎））以及肌炎神经退行性疾病（如神经病性疼痛）和其他具有炎症成分的疾病（如类风湿性关节炎、多发性硬化症、骨关节炎和炎症性肠病（IBD））的治疗和/或预防中有用。